none21noThis multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone (CCyd) in patients with newly diagnosed multiple myeloma (NDMM) ≥65 years of age or who were ineligible for autologous stem cell transplantation. Patients (N 5 58) received CCyd for up to 9 28-day cycles, followed by maintenance with carfilzomib until progression or intolerance. After a median of 9 CCyd induction cycles (range 1-9), 95% of patients achieved at least a partial response, 71% achieved at least a very good partial response, 49% achieved at least a near complete response, and 20% achieved stringent complete response. After a med...
Purpose: Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated tha...
In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the trea...
This multicenter phase 2 study of the European Myeloma Network investigated the combination of carfi...
This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a nove...
This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib pl...
Carfilzomib and dexamethasone (Kd) has significant activity in relapsed and refractory multiple myel...
In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the co...
Background Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious ...
The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but he...
In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the co...
The proteasome inhibitors, carfilzomib and bortezomib, are widely used to treat myeloma but head-to-...
International audienceCarfilzomib, a selective proteasome inhibitor (PI), is approved for the treatm...
Background Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious...
Purpose: Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated tha...
In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the trea...
This multicenter phase 2 study of the European Myeloma Network investigated the combination of carfi...
This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a nove...
This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib pl...
Carfilzomib and dexamethasone (Kd) has significant activity in relapsed and refractory multiple myel...
In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the co...
Background Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious ...
The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but he...
In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the co...
The proteasome inhibitors, carfilzomib and bortezomib, are widely used to treat myeloma but head-to-...
International audienceCarfilzomib, a selective proteasome inhibitor (PI), is approved for the treatm...
Background Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious...
Purpose: Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated tha...
In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the trea...
This multicenter phase 2 study of the European Myeloma Network investigated the combination of carfi...